We have previously reported a frequent occurrence of paraproteinaemia (monoclonal gammopathy) following allo-SCT. This finding was significantly associated with CMV reactivation in multivariate analysis. 1 We did not routinely monitor EBV reactivation in our series, as this was not our practice at that time. The last allo-SCT in that series was performed in 2007, 2 years prior to the publication of the European Conference on Infections in Leukemia guidelines recommending routine EBV viral load monitoring following allo-SCT. 2 Chiusolo et al., 3 cited by Metafuni et al. 4 in their letter to the editor of this journal, also report a frequent detection of g-region abnormalities on serum protein electrophoresis (SPE) following allo-SCT. These abnormalities were significantly more frequent in patients where SPE had been performed at the time of detection of EBV DNA in the peripheral blood, than in patients who did not experience EBV reactivation. SPE in this study was performed at the time of EBV detection for those patients with EBV reactivation, and at an unspecified time for those not reactivating EBV, rather than at pre-specified times for all patients in the study. In the light of this, no formal statistical correlation of the strength of the association between EBV reactivation and g-region abnormalities could be made. Six patients in this study developed posttransplant lymphoproliferative disorder (PTLD), all had a g-peak on SPE and 5/6 patients had a paraprotein detectable on immunofixation. These 6 PTLD patients, and another 12 with EBV viraemia received rituximab therapy. Following this treatment, the g-peak disappeared in 3/4 patients with PTLD and in 9 patients with EBV viraemia, although a paraprotein remained detectable by immunofixation in 2/3 PTLD patients evaluated. Metafuni et al. 4 suggested in their letter that this resolution of SPE abnormalities indicates a causal relationship between EBV reactivation and paraproteinaemia. We feel that, in the absence of control data, and considering that rituxumab will result in pan B-cell depletion and may therefore eradicate potential paraprotein producing clones not proliferating in response to EBV, these data cannot be used to support this conclusion.
Metafuni et al. 4 also comment that in our study we reported poorer OS in association with paraproteinaemia, whereas in the report of Chiusolo et al. there is no association between crude OS and paraproteinaemia although, in the absence of an evaluation of actuarial survival rates, these data must be treated with caution. In our study, we found an association between paraproteinaemia and impaired survival in univariate analysis. We did not, however, find such an association in multivariate analysis, where unrelated donor allo-SCT was the only factor to associate with impaired survival. As more unrelated donors in our study received alemtuzumab, and paraproteinaemia was more common in alemtuzumab recipients, we suspect that the univariate association we reported is due to confounding factors. It remains noteworthy, however, as others have reported improved survival in association with paraproteinaemia post transplant, 5 a finding we did not recapitulate. Although CMV reactivation was the strongest factor associated with paraproteinaemia in our study, a significantly increased incidence of paraproteinaemia also occurred in alemtuzumab recipients who did not reactivate CMV. 1 We raised the possibility that this may be due to EBV reactivation, which is also more frequent in alemtuzumab recipients. In the profoundly lymphopenic environment that exists after in vivo T-cell depleted allo-SCT, viruses provides a powerful antigenic stimulus to oligoclonal lymphoid expansion phenomena. 6 CMV and EBV are the two most obvious candidate viruses likely to drive this process and we suspect both are likely to contribute to the development of the paraprotein epiphenomenon that is so well described after allo-SCT. Only prospective studies can adequately address the question of how best to manage EBV reactivation after allo-SCT in order to prevent progression to PTLD. Great improvements in prevention of post-allo-SCT CMV disease have derived from routine PCR monitoring of CMV viral load. This, coupled with the poor positive predictive value of paraproteinaemia for the development of PTLD, 7 suggests that future protocols designed to standardize the management of post-allo-SCT EBV reactivation, are more likely to be based on viral load monitoring than on the detection of paraproteinaemia on SPE.
